Search results
Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics
Zacks· 4 days agoFree Report) is expected to reveal quarterly loss of $3.59 per share, indicating a decline of 1989.5% compared to the year-ago period. Over the past 30 days, the consensus EPS estimate for the ...
Moderna: Q1 Earnings Snapshot
Midland Reporter-Telegram· 1 day agoCAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Thursday...
Earnings call: Moderna reports a net loss of $12.2 billion By Investing.com
Investing.com· 14 hours agoModerna , Inc. (NASDAQ:MRNA) reported a mixed first quarter in 2024, with significant business...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 23 hours agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 4 days agoInvestors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its...
Moderna Inc [MRNA] Shares Fall
Knox Daily· 6 days agoGenuity has initiated its “Hold” rating for MRNA. Earlier on November 03, 2023, HSBC Securities upgraded its rating. Their new recommendation was “a Hold” for MRNA ...
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks· 4 days agoInvestors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
J.P. Morgan downgrades Metagenomi over Moderna deal termination (NASDAQ:MGX)
Seeking Alpha· 17 hours agoJ.P. Morgan has lowered its rating of Metagenomi (NASDAQ:MGX) to neutral, citing the recent...
Moderna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall By Investing.com
Investing.com· 23 hours agoModerna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,100 Today - Moderna (NASDAQ:MRNA)
Benzinga· 2 days agoModerna MRNA has outperformed the market over the past 5 years by 23.65% on an annualized basis producing an average annual return of 35.34%. Currently, Moderna has a market ...